IDXX vs DXCM Comparison: AI Score, Valuation, Performance and Upside
Compare IDEXX's veterinary diagnostics and testing platform against DexCom's continuous glucose monitoring device business.
Use this IDEXX Laboratories vs DexCom comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
DXCM holds the edge across 3 of 5 key metrics in this comparison. DXCM leads on both 1-year return (+11.38%) and forward P/E quality (29.07x vs 33.15x for IDXX), a relatively favorable combination of momentum and valuation. On fundamentals, DXCM is growing revenue faster (13.10%), while IDXX maintains the higher operating margin (34.98%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for IDXX (+25.93%) than for DXCM (+3.63%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | IDXX | DXCM |
|---|---|---|
| AI scorei | 50.7 | 51.9 |
| AI ranki | #490 | #417 |
| Latest closei | $535.38 | $87.90 |
| 1M returni | -8.45% | +6.34% |
| 6M returni | -13.50% | +24.35% |
| 1Y returni | -15.55% | +11.38% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | IDXX | DXCM |
|---|---|---|
| 1Y ago | $8.36K (-16.4%) started 2025-09-04 | $10.88K (+8.8%) started 2025-09-04 |
| 5Y ago | $7.85K (-21.5%) started 2021-09-07 | $6.37K (-36.3%) started 2021-09-07 |
| 10Y ago | $46.98K (+369.8%) started 2016-09-06 | $37.29K (+272.9%) started 2016-09-06 |
Hypothetical — past performance does not guarantee future results.
| Metric | IDXX | DXCM |
|---|---|---|
| Market capi | $43.72B | $34.27B |
| Trailing P/Ei | 39.06 | 35.90 |
| Forward P/Ei | 33.15 | 29.07 |
| Price/Salesi | 10.74 | 8.19 |
| EV/Revenuei | 9.80 | 6.79 |
| Analyst targeti | $698.92 | $94.12 |
| Target upsidei | +25.93% | +3.63% |
| Metric | IDXX | DXCM |
|---|---|---|
| Revenue growthi | 9.70% | 13.10% |
| Earnings growthi | 17.60% | 43.60% |
| EPS growthi | +17.60% | +43.60% |
| FCF margini | +19.97% | +20.55% |
| Operating margini | 34.98% | 24.33% |
| Profit margini | 25.03% | 20.12% |
| ROIC proxyi | 74.21% | 38.49% |
| Return on equityi | 74.21% | 38.49% |
| Dividend yieldi | N/A | N/A |
| Betai | 1.54 | 1.41 |
| Debt/equityi | 67.97 | 53.35 |
| Current ratioi | 1.17 | 1.73 |
| Quick ratioi | 0.73 | 1.37 |
Over the past year, IDXX and DXCM have moved weakly in the same direction (correlation of 0.39), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | IDXX | DXCM |
|---|---|---|---|
| 1Y | Growthi | -16.40% | +8.84% |
| CAGRi | -16.43% | +8.85% | |
| Volatilityi | 32.10% | 41.04% | |
| Sharpe ratioi | -0.54 | 0.30 | |
| Sortino ratioi | -0.80 | 0.43 | |
| Max drawdowni | 31.34% | 32.10% | |
| Current drawdowni | 30.17% | 4.81% | |
| Avg drawdowni | 16.91% | 14.28% | |
| Ulcer Indexi | 19.93% | 16.14% | |
| Max daily dropi | 5.02% | 14.63% | |
| Max wkly dropi | 8.95% | 17.22% | |
| 5Y | Growthi | -21.46% | -36.27% |
| CAGRi | -4.72% | -8.63% | |
| Volatilityi | 35.69% | 47.29% | |
| Sharpe ratioi | -0.09 | -0.04 | |
| Sortino ratioi | -0.13 | -0.05 | |
| Max drawdowni | 52.79% | 66.32% | |
| Current drawdowni | 30.17% | 46.01% | |
| Avg drawdowni | 27.23% | 40.26% | |
| Ulcer Indexi | 29.77% | 43.38% | |
| Max daily dropi | 9.79% | 40.66% | |
| Max wkly dropi | 21.97% | 42.68% | |
| 10Y | Growthi | +369.84% | +272.93% |
| CAGRi | +16.74% | +14.08% | |
| Volatilityi | 33.00% | 48.72% | |
| Sharpe ratioi | 0.50 | 0.43 | |
| Sortino ratioi | 0.75 | 0.61 | |
| Max drawdowni | 54.00% | 66.32% | |
| Current drawdowni | 30.17% | 46.01% | |
| Avg drawdowni | 17.38% | 28.07% | |
| Ulcer Indexi | 22.87% | 33.92% | |
| Max daily dropi | 11.94% | 40.66% | |
| Max wkly dropi | 27.89% | 42.68% |
| Category | IDXX | DXCM |
|---|---|---|
| Company | IDXX | DXCM |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Medical Devices |
| Core business | IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. | DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States a… |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.